Abdera is developing targeted alpha therapies (TATs) using its ROVEr™ platform, which combines antibody engineering with radiopharmaceuticals to deliver radionuclide payloads directly to solid tumors. The company aims to improve treatment outcomes for patients with relapsed, refractory, and metastatic cancers while minimizing systemic toxicities.
Funding
$142M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
VPFounders
Product
Problem
Many solid tumors are difficult to treat effectively due to their location, resistance to conventional therapies, and the systemic toxicities associated with radiation and chemotherapy. Delivering sufficient radiation doses directly to the tumor while sparing healthy tissues remains a significant challenge in oncology.
Solution
Abdera is developing targeted alpha therapies (TATs) using its ROVEr™ platform to deliver radionuclide payloads directly to solid tumors. The ROVEr™ platform integrates antibody engineering with radiopharmaceutical technology to create cancer medicines with tunable pharmacokinetic (PK) properties. This approach aims to maximize therapeutic effect while mitigating systemic toxicities. Abdera is building a pipeline of radiotherapeutics capable of delivering alpha- or beta-emitting radionuclide payloads to a range of solid tumor targets.
Target Audience
The primary target audience includes patients with relapsed, refractory, and metastatic solid tumors, as well as oncologists seeking more effective and less toxic treatment options.
Features
- ROVEr™ platform combining antibody engineering and radiotherapeutics
- Tunable PK properties for optimized drug delivery and reduced off-target effects
- Capability to deliver alpha- or beta-emitting radionuclide payloads
- Pipeline focused on emerging and clinically validated solid tumor targets